Tacrolimus and fluconazole should not be combined without close medical supervision and therapeutic drug monitoring. Fluconazole is a potent inhibitor of the CYP3A4 enzyme, which is responsible for metabolizing tacrolimus, and this interaction can lead to significantly elevated tacrolimus blood levels, increasing the risk of toxicity including kidney damage, neurological complications, and graft rejection in transplant recipients.
Both the tacrolimus and fluconazole FDA drug labels carry explicit warnings about this interaction, though it is not always emphasized equally in prescribing information. The tacrolimus label (available through the FDA's drug labeling database) identifies that potent CYP3A4 inhibitors can increase tacrolimus concentrations and recommends dosage reduction and therapeutic drug monitoring when such inhibitors are used concomitantly. The fluconazole label similarly warns that it inhibits hepatic metabolism of certain drugs metabolized by CYP3A4, which may lead to increased drug concentrations.
The interaction is classified as a significant or moderate-to-significant clinical concern depending on the clinical context. For transplant patients who are already on carefully titrated tacrolimus doses to prevent rejection while minimizing toxicity, the addition of fluconazole represents a meaningful risk that requires intervention.
No absolute contraindication exists in the FDA labeling—meaning the drugs are not forbidden from being used together—but this is a case where "use with caution" translates into mandatory therapeutic drug monitoring and likely tacrolimus dose adjustment.
Understanding the mechanism is essential for appreciating why this interaction matters clinically. Tacrolimus is a calcineurin inhibitor immunosuppressant used to prevent organ rejection in transplant recipients and to treat certain autoimmune conditions. It has a narrow therapeutic window: too little and the graft is rejected; too much and the patient suffers serious toxic effects including nephrotoxicity (kidney damage), neurotoxicity (tremor, seizures, encephalopathy), and hepatotoxicity.
Tacrolimus is metabolized primarily by the cytochrome P450 enzyme CYP3A4 in the liver and intestinal wall. This is the same metabolic pathway used by hundreds of other medications, making tacrolimus susceptible to interactions with drugs that either induce (speed up) or inhibit (slow down) CYP3A4.
Fluconazole, an azole antifungal agent used to treat fungal infections including Candida and Cryptococcus species, is a potent and competitive inhibitor of CYP3A4. When fluconazole is added to a patient already taking tacrolimus, the following occurs: CYP3A4 enzyme activity is reduced, the breakdown of tacrolimus slows down, and tacrolimus accumulates in the bloodstream. Peak plasma concentrations of tacrolimus can increase by 40% to 70%, and area-under-the-curve (AUC) values—a measure of total drug exposure—can rise substantially.
This is not a case of mild competition at the enzyme level. Fluconazole's inhibition is competitive and dose-dependent, meaning higher fluconazole doses produce stronger inhibition. The effect begins within 24–48 hours of starting fluconazole and can persist for several days after fluconazole is discontinued, since fluconazole has a half-life of 20–50 hours.
The severity of this interaction is determined by several factors:
Certain patient populations face particular danger from the tacrolimus-fluconazole combination:
Solid organ transplant recipients are the primary at-risk group. Kidney transplant, heart transplant, liver transplant, and lung transplant patients all depend on stable tacrolimus levels to maintain graft viability. Fungal infections (particularly candidiasis and cryptococcal meningitis) are not uncommon in immunosuppressed transplant recipients, making this interaction a real clinical problem that transplant teams face regularly.
Patients with baseline renal impairment are at elevated risk because tacrolimus is already cleared slowly, and the CYP3A4 inhibition compounds the problem. A transplant patient with a serum creatinine of 2.0 mg/dL is at higher risk than one with a creatinine of 0.9 mg/dL.
Patients on other CYP3A4-metabolized drugs face additive burden. For example, a transplant patient on tacrolimus and diltiazem (a calcium channel blocker that is also metabolized by CYP3A4 and is itself a mild CYP3A4 inhibitor) who then starts fluconazole faces a compounded interaction.
Patients with severe underlying fungal infections (such as invasive candidiasis or cryptococcal meningitis) may require prolonged fluconazole therapy at higher doses, which increases the risk of sustained elevation in tacrolimus levels.
A 56-year-old man is 18 months post-kidney transplant, maintained on tacrolimus 5 mg twice daily with a trough level of 8 ng/mL (within therapeutic range). His serum creatinine is stable at 1.2 mg/dL, indicating good renal function. He develops oral candidiasis (thrush) and his primary care physician prescribes fluconazole 150 mg daily for 14 days for local control. The transplant team is not directly consulted.
Without dose adjustment or monitoring, the patient's tacrolimus levels rise to 15 ng/mL by day 5 of fluconazole therapy. He develops symptoms of tacrolimus toxicity: tremor, insomnia, and elevated creatinine (1.6 mg/dL). The rise in creatinine triggers concern for graft dysfunction or rejection. In reality, the problem is drug-induced toxicity, not rejection.
What should have happened: The transplant team should have been informed before fluconazole was started. The tacrolimus dose should have been reduced to 4 mg twice daily at initiation of fluconazole. Tacrolimus trough levels should have been checked on day 3–5, and the dose adjusted further if needed. Alternative antifungals with less enzyme inhibition (such as nystatin oral suspension for thrush, which is not systemically absorbed) should have been considered first.
A 62-year-old woman is 4 months post-heart transplant, on tacrolimus 6 mg twice daily (trough 9 ng/mL) plus standard immunosuppression. During hospitalization for pneumonia, blood cultures grow Candida auris, and she is started on fluconazole 400 mg IV daily. Her renal function is borderline (creatinine 1.3 mg/dL), and she is also taking diltiazem for rate control of a new atrial arrhythmia (another CYP3A4 substrate).
Over 10 days of fluconazole at high dose, her tacrolimus trough level climbs to 18 ng/mL. She develops acute kidney injury with creatinine rising to 2.1 mg/dL, complains of severe headache and blurred vision (signs of neurotoxicity), and her graft function deteriorates. The clinical team must distinguish between graft rejection, acute kidney injury from sepsis, and tacrolimus toxicity. Stopping or reducing fluconazole is not immediately attractive because she has a life-threatening fungal infection.
What should have happened: On the day fluconazole was initiated at high dose, the tacrolimus dose should have been reduced to 4 mg twice daily. Tacrolimus trough levels should have been checked every 2–3 days given the high-dose fluconazole and baseline renal impairment. If levels remained elevated, further dose reduction would be needed. Consideration should have been given to alternative antifungals with less CYP3A4 inhibition (such as anidulafungin or micafungin, echinocandins that do not significantly inhibit CYP3A4), though the choice would depend on organism susceptibility and clinical judgment.
For patients: Inform your transplant team, nephrologist, or physician immediately if you are prescribed fluconazole or any antifungal while taking tacrolimus. Do not start fluconazole without explicit approval from the provider managing your tacrolimus. If fluconazole is deemed necessary, follow up with blood work (including tacrolimus trough level and serum creatinine) within 3–5 days of starting the interaction. Watch for symptoms of toxicity (see red flags below) and report them promptly. Do not adjust your tacrolimus dose on your own; wait for your doctor's guidance.
For healthcare providers: When a tacrolimus patient requires treatment for a fungal infection, consider the interaction and select the antifungal thoughtfully. For localized infections (oral candidiasis, vaginal candidiasis), non-absorbed alternatives like nystatin suspension or topical azoles are preferred. For systemic infections where fluconazole is necessary, reduce tacrolimus dose by 30–50% at initiation. Order tacrolimus trough level 3–5 days after starting fluconazole (and again 1–2 days after stopping it, since levels may drop and require re-uptitration). Monitor serum creatinine, potassium, and liver function tests. Consider alternative antifungals with minimal CYP3A4 inhibition (echinocandins, amphotericin B formulations) if the clinical situation permits and the patient can tolerate them. If tacrolimus must be held or reduced significantly, communicate with the transplant team about graft rejection risk and immunological monitoring.
Practical dosing approach: While individual pharmacokinetics vary, a typical approach is to reduce tacrolimus by 30–50% when fluconazole is started, then titrate based on trough levels. For example, a patient on tacrolimus 5 mg twice daily might be reduced to 3 mg twice daily during fluconazole therapy, with recheck levels at day 5. As fluconazole is discontinued, tacrolimus is re-escalated over 3–5 days to prevent graft rejection from under-immunosuppression.
Contact your healthcare provider immediately if you experience any of the following while taking tacrolimus and fluconazole together:
If you notice any unusual symptoms, call your pharmacist or doctor before the next scheduled dose.
If you take tacrolimus and are about to start fluconazole or any other medication, or if you are unsure whether your current medications interact, use checkdruginteractions.com to check your full medication profile. Our comprehensive drug interaction checker is powered by over 250,000 FDA drug labels and the latest clinical data. Enter all your medications—including over-the-counter drugs and supplements—to get an immediate, evidence-based assessment of potential interactions. When in doubt, share the results with your pharmacist or doctor to ensure safe, effective treatment.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.
FDA data shows major interaction risk between metoprolol and diltiazem. Learn symptoms, safety, and management from clinical pharmacists.